Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DNA repair protein RAD51 homolog D (RAD51D)
- Target
- RAD51D
- Molecular classification
- DNA repair enzyme, RAD51 family, Homologous recombination protein
01
Overview
DNA repair protein RAD51 homolog D (RAD51D) is a member of the RAD51 paralog family involved in homologous recombination, catalyzing the repair of DNA double-strand breaks to maintain genome integrity[5][7]. RAD51D forms part of the BCDX2 complex (RAD51B-RAD51C-RAD51D-XRCC2) which stabilizes and directs RAD51 nucleoprotein filament assembly on single-stranded DNA, enabling accurate DNA repair, replication fork stability, and prevention of chromosomal deletions[1][5]. Mutations in RAD51D are associated with a predisposition to breast, ovarian, and prostate cancers as well as Fanconi anemia, and they confer sensitivity to PARP inhibitors through synthetic lethality[5][6][7]. RAD51D is considered a validated therapeutic target in the context of HR-deficient tumors.
- Other names
- RAD51DRAD51L3RAD51 homolog DRAD51-like protein 3TRADHsTRADR51H3DNA repair protein RAD51 homolog 4BROVCA4recombination repair protein
02
Mechanism of action
Synthetic lethality: Inhibition of PARP in RAD51D-deficient cells leads to unrepaired DNA damage and cell death
03
Biological functions
Homologous recombination (HR)DNA double-strand break repairGenome stabilityReplication fork protectionChromosomal stability
04
Disease associations
Cancer (breast, ovarian, prostate)Fanconi anemia
05
Safety considerations
Risk of secondary malignancies due to genome instability in long-term therapyMyelosuppression and related toxicities when using PARP inhibitors in patients with impaired homologous recombination
06
Interacting drugs
PARP inhibitors (e.g. olaparib, rucaparib, niraparib) in context of homologous recombination deficiency
07
Biomarkers
Germline or somatic RAD51D mutations for PARP inhibitor eligibility in ovarian cancer
Beyond the preview
Go deeper on DNA repair protein RAD51 homolog D (RAD51D).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DNA repair protein RAD51 homolog D (RAD51D).